<SEC-DOCUMENT>0001193125-13-001642.txt : 20130103
<SEC-HEADER>0001193125-13-001642.hdr.sgml : 20130103
<ACCEPTANCE-DATETIME>20130103074533
ACCESSION NUMBER:		0001193125-13-001642
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121228
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130103
DATE AS OF CHANGE:		20130103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		13504054

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d460909d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d) OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>THE SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): December&nbsp;28, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction<BR></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission<BR>File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer<BR></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02453</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (781)&nbsp;250-0111 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report.)
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;28, 2012, Repligen Corporation (&#147;Repligen&#148; or the &#147;Company&#148;) entered into an exclusive worldwide licensing agreement (the &#147;License Agreement&#148;) with Pfizer
Inc. (&#147;Pfizer&#148;) to advance the Company&#146;s spinal muscular atrophy (&#147;SMA&#148;) program which is led by RG3039, a small molecule drug candidate in clinical development for SMA, a rare neurodegenerative genetic disease, and also
includes backup compounds and enabling technologies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the License Agreement, Repligen is entitled to receive up to $70
million from Pfizer, commencing with an upfront payment of $5 million and total potential future milestone payments of up to $65 million, approximately equally divided between milestones related to clinical development and initial commercial sales
in specific geographies.&nbsp;In addition, Repligen is entitled to receive royalties on any future sales of RG3039 or any SMA compounds developed under the License Agreement.&nbsp;The tiered and increasing royalty rates under the License Agreement
begin in the high single-digits.&nbsp;Repligen&#146;s receipt of these royalties is subject to an obligation under an existing in-license agreement&nbsp;and other customary offsets and deductions. Royalties are payable, on a country-by-country
basis, for a duration based upon the later of (a)&nbsp;expiration of the licensed patent(s) or (b)&nbsp;a predetermined time after the first commercial sale of the first such product in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the License Agreement, the Company is responsible for completing the first two cohorts of an active Phase 1 trial evaluating RG3039 in
healthy volunteers, which it anticipates will occur during the first quarter of 2013. The Company will also provide certain technology transfer services to Pfizer who will then assume full responsibility for the SMA program moving forward, including
the conduct of any registration trials necessary for any product approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The License Agreement is subject to termination by Pfizer for
convenience and by either party upon the uncured breach or bankruptcy of the other party. Under the terms of the License Agreement, neither party may assign the License Agreement without the prior written consent of the other party; however, either
party may assign the License Agreement (i)&nbsp;in connection with the sale of such party or the sale of the portion of its business to which the License Agreement relates (whether by merger, sale of assets and/or sale of stock or ownership interest
or otherwise), and (ii)&nbsp;to its affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects to file the License Agreement as an exhibit to its Annual Report on Form
10-K for the year ending December&nbsp;31, 2012 and intends to seek confidential treatment for certain terms and provisions of the License Agreement. The foregoing description is qualified in its entirety by reference to the complete text of the
License Agreement when filed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;3, 2013, the Company issued a press release concerning the License Agreement, which is attached
hereto as Exhibit 99.1 and is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated January&nbsp;3, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: January&nbsp;3, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Walter C. Herlihy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Walter C. Herlihy</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT INDEX </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:25pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated January 3, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d460909dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="26%"></TD></TR>


<TR>
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g460909ex99_1pg1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ROWSPAN="6" VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="6"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 Seyon Street</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite
100</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02453</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone: (781) 250-0111</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax: (781)
250-0115</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Announces Licensing Agreement with Pfizer </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>for Spinal Muscular Atrophy Program </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; January&nbsp;03, 2013</B>
&#150; Repligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Repligen&#146;s spinal muscular atrophy (SMA) program, originally in-licensed from Families of
SMA (FSMA). The SMA program includes RG3039, a small molecule drug candidate in clinical development for SMA, as well as backup compounds and enabling technologies. Under the terms of the agreement, Repligen is entitled to receive up to $70 million
from Pfizer, commencing with an upfront payment of $5 million and total potential future milestone payments of up to $65 million as well as royalties on any future sales of SMA compounds developed under the agreement. SMA is an orphan
neurodegenerative genetic disease that presents early in life. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This agreement is consistent with the strategic decision we announced in
August 2012 to focus Repligen&#146;s internal efforts on the growth of our bioprocessing business, while seeking external partners for our therapeutic development programs,&#148; said Walter C. Herlihy, Ph.D., President and Chief Executive Officer
of Repligen. &#147;We believe this collaboration with Pfizer, a leading pharmaceutical company with specialized efforts in orphan and genetic diseases, has the potential to accelerate the development of therapies for SMA.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;There is a critical need to expedite potential treatment solutions for rare diseases such as spinal muscular atrophy, where patients have such
limited options,&#148; said Jose Carlos Gutierrez-Ramos, Senior Vice President, Pfizer BioTherapeutics R&amp;D. &#147;This partnership will combine our expert capabilities in advancing molecules for genetic diseases with Repligen&#146;s leading SMA
program.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the agreement, Repligen is responsible for completing the first two cohorts of an active Phase 1 trial
evaluating RG3039 in healthy volunteers, which it anticipates will occur during the first quarter of 2013. Repligen will also provide certain technology transfer services to Pfizer who will then assume full responsibility for the SMA program moving
forward, including the conduct of any registration trials necessary for product approval. Repligen has previously received U.S. Orphan Drug and Fast Track designations for RG3039 for the treatment of SMA, as well as Orphan Medicinal Product
designation in the EU. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program,
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>January 03, 2013 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
Page
 2
 of 4 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This licensing deal demonstrates the innovative collaborations that Families of SMA has
successfully implemented between non-profit, biotech and big pharma,&#148; stated Jill Jarecki, Ph.D., Research Director for Families of SMA. &#147;These partnerships are critical for the development of new treatments for an orphan disease such as
SMA. We are extremely pleased to see Pfizer taking the lead on the development and commercialization of the SMA program, following Repligen&#146;s development work and FSMA&#146;s original investment.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Families of SMA, a patient organization dedicated to funding research to advance therapies for SMA, funded and directed the preclinical development of
RG3039 with an investment of more than $13 million. This was the first drug discovery program ever conducted specifically for SMA. Repligen&#146;s research and clinical efforts, including the current Phase 1b trial, have been partially supported by
a $1.4 million grant from the Muscular Dystrophy Association. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Spinal Muscular Atrophy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease in which a defect in the SMN1 (survival motor neuron) gene results in low
levels of the protein SMN and leads to progressive damage to motor neurons. It is the leading cause of infant mortality and the second most common inherited neuromuscular disease, with symptoms that typically emerge before the age of two. SMA is
characterized by progressive muscle weakness leading to severe physical disability and often, early loss of life due to respiratory insufficiency. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Families of SMA </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Families of SMA is the world&#146;s leader focused on funding SMA
research to develop a treatment and cure for the disease. The successful results and progress that the organization has delivered, from basic research to drug discovery to clinical trials, provide real hope for families and patients impacted by the
disease. The charity has invested over $55 million in research and has been involved in funding half of all the ongoing novel drug programs for SMA. Families of SMA is a nonprofit 501(c)3 organization, with 31 Chapters and 90,000 members and
supporters throughout the United States. The organization&#146;s work has produced major discoveries, including identification of the underlying cause and a back-up gene for the disease, which provides a clearly defined target for disease altering
therapies. The organization is also dedicated to supporting SMA families through networking, information and services and to improving care for all SMA patients. For more information: www.curesma.org. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program,
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>January 03, 2013 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
Page
 3
 of 4 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About the Muscular Dystrophy Association </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Muscular Dystrophy Association (MDA) is the leading nonprofit health agency dedicated to finding treatments and cures for more than 40 neuromuscular diseases, including SMA, by funding worldwide
research. MDA also funds comprehensive health care and support services, advocacy, information and education, and accessible summer camp for thousands of youngsters fighting progressive muscle diseases.&nbsp;To date, MDA has invested more than $41.6
million in SMA research, funding basic research and clinical trials of therapeutic strategies such as&nbsp;gene-based therapies, small-molecule development, and stem cells.&nbsp;MDA, along with other SMA patient advocacy groups, has been working
with policymakers to explore the potential of expanding newborn screening panels to include SMA.&nbsp;For more information, visit&nbsp;mda.org&nbsp;and follow MDA on Facebook (facebook.com/MDAnational) and Twitter (@MDAnews). </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Corporation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen
Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences
and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used during the production of monoclonal antibody therapeutics. We also supply several growth factor products used to increase cell culture
productivity during fermentation. In addition, we have developed and market a series of chromatography products used in the purification of biologics, and sell test kits to ensure final product quality. Aside from our core bioprocessing business, we
have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and two central nervous system orphan drug candidates. Repligen&#146;s corporate headquarters are located in Waltham, MA, USA; we have
an additional manufacturing facility in Lund, Sweden. For more information, please visit our website at www.repligen.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press
release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding the potential utility of RG3039 for the treatment of SMA, the clinical success of
RG3039 and its further clinical development and our receipt of any future payments under the terms of our agreement with Pfizer, Pfizer&#146;s ability to terminate the license agreement for convenience, our strategic decision to focus on the growth
of our bioprocessing business, the future demand for our bioprocessing, growth factor and chromatography products, plans and objectives for future operations, our ability to successfully negotiate and consummate partnering transactions for our
clinical stage assets, specifically RG1068, RG3039 and RG2833, plans and objectives for product development and acquisitions , plans and objectives for regulatory approval, product development, our market share and product sales and other statements
identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials, including our Phase
1b clinical trial of RG3039 in patients with SMA; our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully negotiate and consummate
development and commercialization partnerships for our portfolio of clinical-stage assets on acceptable terms, if at all; our ability to develop and commercialize products and the market acceptance of our products;
</I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program,
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>January 03, 2013 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
Page
 4
 of 4 </I></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; the ability to obtain, and the timing and receipt of, FDA
approval for our NDA for RG3039; our ability to obtain other required regulatory approvals; the success of current and future collaborative or supply relationships, including our agreement with Pfizer; our ability to compete with larger, better
financed bioprocessing, pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our compliance with all Food and Drug Administration and EMEA regulations; our ability to obtain, maintain and protect
intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales capabilities; our volatile stock price; and other risks detailed in Repligen&#146;s Annual Report on Form 10-K on
file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking
statements. These forward looking statements reflect management&#146;s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the
date hereof except as required by law. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Sondra S. Newman </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director Investor Relations </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">snewman@repligen.com </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781) 419-1881 </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I># # #
</I></FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g460909ex99_1pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g460909ex99_1pg1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)`".`P$1``(1`0,1`?_$`&L```(#`0$!````````
M```````)!P@*!@,%`0$`````````````````````$```!@(!`P0"`@("`P``
M```"`P0%!@<!"`D`$@H1$Q06(147&2(8,2-!1"41`0``````````````````
M``#_V@`,`P$``A$#$0`_`-SM^VVQT#1=S7I)<9%'J:JJP;3>RPA,&,YK@$4=
MI4N(*+)"(XTY0G:A```&,C&,6,!QG.<8Z#!;77EZ<F=P-S@\5+Q>0ZT6EI6@
M;75TKIHO^;-S8XFD!5%H'!=&D3FF1+3$PL&!*,$$S(,X%C'I^>@D!A\QK:*G
M;`CK+NUQEJZUB<@-1GY"SNMC5Q.R6#"SXKR_,3%:T8-0RW*`!H1EIPG("C32
M_:&I*]S!A8;H:8MZ!7_4E:WA5KT"1UQ;4(C5A0A[`6(G+C&I8TI7EI4&IQ_]
MB55\16'!Q(_\R3<"`+T$'/029T!T!T!T&:'G+YT;>XN[[U1UUH2BZVNJ>[&-
M#FZ+2["D<C9B6,Q9,F:#P=(@(C0L*!_O'@]=[QIWX`%.'!819R+M"U'-'R:[
M"\:&OE,3RB-93-FK?L^?@BSQ#&UHGCRP1EA:HFN>9/(COI*-8^%E%/>42-)D
M[`"QX4"R(7<'&,@QS72YYA+=1ZAV!V59HI24NDE(1:VK?8C'50W1&KCG:*)I
M9(4#B\2<Q,>W((FC/$%8<M&#V,DF9,SC`<]`D20<]=Q[,3B:0+A]X[K9WWC\
M%>%$:?MG9/)4%&ZQCD"<)X3$T1EDH1>]-4Q)I`NX63VHX>`A&4680<2H$')P
M7R`+ZUVO2JZ!YA>/B8:*!N20IX;`]BXU-4=DZ_.$K6*TJ5,E=GA,G,2LC.#*
MXH2M62[N1C>#.35!!:8)AY8:@>@.@.@.@.@0UY+M["H?AIVV6I5BQ"\6FUQ"
MD&4Y"9@H\1EE2YH;'T@0\YQZ)E$/3N0#L8_.2A"QC\]!GQ\9GE7XJN.[CO=J
M\V3VR9:SO.S+\L&SYC#G*N[AD:AD;/U45@T22@=(56;ZQ&)EC)#0KPA"L/-`
M-</`\@_!8`@SG^WAJ[GEMO3;1OBNB4DVEF<0F,METBM1J@4KC+,S"EC>RQ],
MT%+IA'F-X9(2UI4I[E(W9>2C;2/C).T1H@"[`;EO]R>2?@ZUPT2XF=*8$T[#
M;YN]+5C6\;0K"7!\C\/]Y,1"&B4"C2,3<Z2Z4V-8!"W]$U&&I""R"#%"P608
M*(4@J_=*^/+`XTZ^:M[-DM@JX>*R4/T6CDMKN/H*FFD5A3A)%9OZAMF,(8X&
MRIFU`Y*DF$1KBT.1V"SU19.%(!C*%T&@V[N9>1/GCRN?*M5WUZK[CF50MJ&,
M-:P@M^8XK?"FS"Z;D;<T('T(\/*!JEJ!R4M9:P!OO)2B1'!,#D7<"0M*MZ/)
MSY0M)C7;5(4%8STTZFY<LVWLYMJ:NETV[$B%L::KH./BB@V+#5#,MYBESD"A
ML/-->G$:,*XDM&,GH)9\>+FRY`;1WWGW&%R+N9]ASEJ0V>SLDK?V..,UD5S:
M=(GN'WB#R]PBJ9O9Y2S+D32O+"H&4:J)7(RNP\PD\7:%4]V!?[[>8-0%,E$-
M[O$]<I;2<94$J33'-`K9J)@J_9>?%*$@"#2$2PF2.3F@]O/<#!J<`C!!SD00
M`PGGMY4MZJ8Y5-'^/S1NZ4]3F6TSU2@L$]/'8G*SG.7WE<BJ$1]([)GZ./RQ
MJ31Z.LQ2L&4HBS3RW,>1!]`%"R%B_(.LZQ=E[\T#X0JCDLAC0=VYNW3G:"7,
MYP270K7&".QQZYC]\D&<"+=Q1EV=EH,A+`,;*D*%@PA2<7D-""`G5'CJUA8&
MA2[UEK)J]1,<C<41.LG>6F%P2(MBIR;XXS9>']V/2(\N<@D+J2`U4I-$I<')
M9D9@QG&Y$(%+;^[&\#W)S1!6LVPO(?K`KB!\ZBDU9U,`V7JMFFC?*XX>I*:Q
ML+JI4O8DIB\AR/2'!+(R8<2>(&,XSGUZ"U')QR)-/&50E31^OX`][";1WG)X
M_06H]")E9@W^T;%&B1MY#O*%B?!:TB)1P)J8QW5$@"8:I5ITX<DY4^^2"K;>
MU$\E$NI)#M.?RI5#&[SAD1>+%*T^KR@8J11V,-C>ID"ZM0V`\)7%=(G%,D(R
MB2JW!N4%&J`!P-9D`QJQ!+`^:J?3+QT))RI-J>*UKL(55CW%4:16A3+XDGO]
MLLX=*$.K$R.IC@G7-+U(`8>4#:I$?V%'!3'9,[!BR$545%>?[D[U!I.ZQ[I5
M[QQ,\HI^'/<4:H]2K-85T7F]*&<ARS;]HNIF(ZPT[&9\M$!6U1]@2*1IF4\'
MRL&&Y]!!5_7/E:Y.;?X?.0D#[8$'0;]ZD;BT?IA#+\0QZ-89']XM?9VEJ57.
MKRPF1O,5^8T)IJY)0.);=C(TYA"K)&%)>1C#@?-QO8QGU\TJUH;SC_=L:W)Y
M<3Z40LR4#X-6Q1)$&%*L1!!W+2G%PM-4:7G(\`*,0>N0B$(&0`P;4#Q?.(M;
MJEK@X7SJ0MEEVN](5B]6S(U]Z;$,2UQL1ZAS0ZR\PYGB5NL\8;A)WU8>5@I$
MD(3!"7CM!C'09D-`J/;-9?*[-UIT=?Y9%Z-K6_+)BCVR-TX<W9.;5\0JQY=;
M"@TL<5*\X^6,['*B%"$)#@)4H)4IRA&"RI)]W`<%MO`2=O/*;O.L-CMD9'I:
MG57@\16%WJT/Y#,]5^16M-)\4(HCCV_.;4ACQ\]*8&?XY@5"<`%#OD1>>\>,
MY"^V_/'YQWT@KC&NVY'D.[KV@OL\]"K;*69FJ7;/FN"Q&Y(@1X4@A==.%B%-
M+BN=E17ZDIP))4+#@Y$F"/LSG`=9Y',#@?&OPC<>'&74$JE+S'Y5:SY-%;G,
MV`;#+Y7&(:5);'DJN5M`\`'&7(ZR[H;#O@&!"81\7V<8#@@8<!H!XRN0/C6U
M9X9]3YB=LS2D.KZI=:X=F:QPRP8V;/D-D!:1N-@Q;,$,=,2];.G:P5#C[3>%
M+E0I--P,O&2<X'T&>+QG*NG6[O+1O-S$39C>(K5#3);R?(RXN9GH@/L*_I"Y
MN>8BF7#)P2Z)*UJI8H"N]K(<)AJ4'K^!]O0>7C,)!;D<YO(]OHXB)<&UG07'
M(H^M3HLFH!.U^W!@F.JTBX[&<IC@0./.)8<8]!F%*!?\!]<9#RJ#)6^7F2SR
M7`4(7:(ZP3>:*0*6],)Q0=FL]5EUDV!//'DPE,K2VB,H7NX],`4E8P#T%Z9Z
M!@^]TE:M3_*WT&V4V$>D40H:XM;':I8!/Y"JRDBC'.%$<M6`FM+DZK?;:V3!
M,KF[4-0<88`I.4[E'&B`'.1]!K8NFD:2V2K5UJ^^ZV@5QU0_F-3H\0JPF)JE
M<-=C&1<F>V9<N:G4E2VJ_P!:XI"E1!@@YP6:6$P.<9QC/080][HGQ>WKS&<8
MW'WQV:Z:Z1<J";51^?;1W-K[6D7;T#FJKE4AEJ^ETLKC"%.VR!OCL:9UBF1>
MV<H3(U:Q&#.<'ISB\!;SE6J&9;L^23J-JVJVCL#3@NO=)7BQ=?[:K+*=%/#K
M,>I#89TH;X6XK7)O(+>7U@8QDF"*&%1A,U#`'&<C#GH)BW-XY)SI+0\HNW:[
MR/>2N$52E$DCBT*J0+'YWE"^2*"VA-&(U$FF3+7Z6NSCA6+(DB).<;A,$TT>
M`E%C&$*F<D>H\.UKXFN);A]HZ9V+.V+=S>2#G">)_$4\!M9WJV2RMVM"3C<8
MFH+P7#'F*/-G1_!A*HO*A/A'V'E8,$:$(;1+>F\=USUYLRQ"T[>UQ:C:<E\O
M3HAF$-[:B9:XAC@[)4&#!!PG2)"DC.$H/X[0!]/Q_P".@PLU-7,MKGQ`=H-A
M"T2C^1=@-@8MMTJ5$IUQ3R(J,;X46E1*5;@$&7-44F0U:>X%K1>G8G49.P+L
MQWY#2/R:<"VL'*IL'3M_[#6K>C(HIJ*M4-9Z[@#G`V^#OK(BF+A,'(I]_>09
M]D>3Y">X92*QIEZ?.$I8,%>V/'?D'BEEEDEEDDE@***`$LHHL(0%EE@#@("R
MP!Q@(``#C&,8QC&,8QT"%M8O'XUKU4Y&YOR7P&\]A'BX+"GEY3N2PF5JJO<*
MZ4*+\<)&Z2QI3E(ZX02Q,A;ETB$-$:%T^6'!`,'&FX$;@8=OR6<`?'WRBS,%
MLW;&YS`+P!'T\;.N"FY(BC$F>VQO*`0R@EC8],LDBLH/8DP/92*%2'*HM/VD
MY-R2`LL`<EQ_>.3QH\>=@,-RP&!R^X;LBV$I\7M"^I$BF;G$W=.G.3CD,3CC
M6RQV&L<@-P>(0%H6\:I*+TRG,)SCUZ#-IY'63MWN?3CGT'2I376/QDJEH[*F
M9<KP6SJ,7-9V)1/C\%DF`.*,_C)D28.SD01C`4'`,A_YR#K;7\2'BAM:_7V[
M3TEZPEEE+Z]R:14M`[":&2L%#R^N(W-7AG`?$5\OC#,!2<9@I`@="4Y!8^PG
M!8`@"$'N073VDJ7U8=-0]=(RDU\JLZNY=7\<#6Z)O`ZQ(R7LC@TK)FC/D"5[
M(?9J4J<,KQKG<"\:Q:#`U7O8R(.0I/Q,<,VN_$!'KHC]#6#;EC8O!ZA[Q)7.
MW%D+6N+;]*0OB)L0,HX;#H@26B.^P'F'8/`>+)F`]N0XQG&0X7COX+]=^.C:
MN^-PX)<=Z6U;FPS1+VZ<&VNIK@QE3+)U/V^QY,],B2%P")*D;@X/R#`>T9YA
M`2#!!P#U[1!"]F\F@>K/(O3!]%;75LDGT/`XEOL=<DRHYEF4&DA1)B8N20>5
MH>USC[ME*<,DWLR(A40,12@HTO.0=`G>%>,#I]'`+XK*=LN1FRJ1.*(;VW7F
M4;5O;;4K;'2#Q'?51L\08XXO7Q\T&<%B)&H#GL#_`(B"+.19!G]><56D%/6S
MJ_;U/T^CJIWT^@]G0&D8S!5QS/"FEIM](!'.G.1LP@J%<PE+L6'(QNCBJ/6F
M'"$::889GNZ#X/(AQ-:C<F*2O'"^VB:QFSJA5JUM4WC3TL/K^W8(-7G)YB-K
ME"9*N+5-(7,!2TM,J(.`0L*P:3DH8C,C"KFM_C[:8TO9\&N^Y[`V=WOM^L5(
MUU;R[=NZ7:Z$$#<@N!#BB=HU#3D33$R'1K4)@"3&J4JK!!H`G`"$\`#0A<G9
M#CBJC:'<;3C<BQYU90)#I*MESW5M8,ZV-D5F[RJ7)P$J)3+$JN.+9*J=FP:-
M&8F^(XI"@C0E=X1AR/`PL!MSK?'-P-9KMU>F,HE4+B5ZU^^5O*)+"#&<J5ML
M>D9(4;S^E-?VI\9RU2QN$8GR(](>'!9HLX#W>F<!!G]=%+?UM?UA?O)I_"7^
MM'^LGV[Y+%_(GU_ZK];^Z_*_1_6?NGR__I]_ZWX/SOS\?VO^OH+_`'0'0'0'
M0'0)P>OZ3O[-"/L7^K/]IOVAA^)^Z]/Y^^U_Q>W?6OA?._'[#^*_C?#]K_T>
:SV_\N@<?T!T!T!T!T!T!T!T!T!T!T!T'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
